Pag-aaral pangklinika para sa Lymphoma sa Kansas
7 pag-aaral para sa Lymphoma ang naghahanap ng mga kalahok sa mga site sa Kansas.
Mga Lungsod sa Kansas
Opisyal na teksto ng pag-aaral (English)
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- University of Kansas Medical Center, Kansas City
Nagre-recruitPhase 1
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT05798897Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Kansas City
Nagre-recruitPhase 3
Edad 18 hanggang 18 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07509151A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Kansas City VA Medical Center, Kansas City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06624085A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Kansas Cancer Center, Westwood
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- University of Kansas Cancer Center, Westwood
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
Nagre-recruitPhase 2
Edad 18 hanggang 66 · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06859424A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- University of Kansas, Westwood
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 14, 2025 · NCT05643742Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.